pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals is a pharma organization headquartered in cardiff, GB. It trades on NYSE under ticker BDRX. Primary therapeutic focus areas include Familial adenomatous polyposis (FAP), Familial Adenomatous Polyp
Company details
- Status
- Public
- HQ
- cardiff, GB
- Founded
- 2000
- Employees
- 25
- Programs
- 4
- Drugs
- 5
- Patents
- 2
Encapsulated Rapamycin (eRapa)
Phase 2 · small molecule · Familial Adenomatous Polyposis
Encapsulated Rapamycin (eRapa) for Familial Adenomatous Polyposis is a Phase 2 program (small_molecule) at Biodexa Pharmaceuticals Plc with 1 ClinicalTrials.gov record(s).
Internal code EMT-FAP-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biodexa Pharmaceuticals Plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Familial Adenomatous Polyposis
- Status
- active
- Trials
- 1